|
employed for the selected existing anticancer drugs such as doxorubicin and taxol/taxotere, and anti-viral agents such as AZT, so that out-licensing of the proprietary delivery technology for the specific drug molecules, as if each represents an NCE, would be attractive to the appropriate corporate partners. The research and development program largely directed toward generating a more diverse menu of molecular carriers, their practical applications, and preclinical path/tox studies will result in the enhanced value of the platform technology. Acornex plans to carry out the early phase research projects in the laboratory of Professor Chung, the chief scientific advisor, and to outsource the bulk of the scale-up supplies (e.g. more than 100g quantities) of the selected carrier-drug conjugates for the animal studies. Strategic partners and investors will provide the initial financial resources, and then subsequently license fees, milestone payments, royalties and additional equity investment by corporate partners are expected to generate an increasing stream of incomes.
|
